Sanofi SA is to acquire an experimental biologic for the treatment of alpha-1 antitrypsin deficiency (AATD), a rare disease of the lungs and liver, in a deal valued at up to $2.2 billion. The asset is currently being developed by Inhibrx Inc, a Nasdaq-listed company in the US, which has a pipeline of four main assets. Sanofi will acquire INBRX-101, a recombinant fusion protein which is in a registrational trial for patients with AATD. The deal was announced on 23 January.
